deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03836066

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (TELMA)

A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.

Sponsor: Fundación GECP

Conditions Non Small Cell Lung Cancer
Interventions Atezolizumab-Bevacizumab
Updated 19 times since 2019 Last updated: Nov 17, 2025 Started: May 15, 2019 Primary completion: Oct 21, 2024 Completion: Oct 21, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03836066, this PHASE2 trial focuses on Non Small Cell Lung Cancer and remains completed. Sponsored by Fundación GECP, it has been updated 19 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jun 2020 · 6 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~May 2023 · 10 months · monthly snapshot~May 2023 – ~May 2024 · 12 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

19 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Jan 2026 [monthly]

    Completed PHASE2

  3. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. May 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  8. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Jun 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  10. Dec 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

  11. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  12. Jul 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. May 2019 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE2

  14. Mar 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fundación GECP
Data source: Fundación GECP

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Alicante, Spain , Badalona, Spain , Barcelona, Spain , Castelló, Spain , Córdoba, Spain , Elche, Spain , Jaén, Spain , Lugo, Spain , Madrid, Spain and 9 more locations